BTIG Research Forecasts Strong Price Appreciation for Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma (NASDAQ:TBPHGet Free Report) had its price target lifted by stock analysts at BTIG Research from $24.00 to $25.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s target price indicates a potential upside of 122.82% from the stock’s current price.

A number of other equities research analysts have also commented on TBPH. Jones Trading upgraded Theravance Biopharma to a “strong-buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 21st. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Theravance Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

View Our Latest Stock Report on TBPH

Theravance Biopharma Trading Up 4.6%

Shares of NASDAQ TBPH opened at $11.22 on Friday. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.82. The firm has a market capitalization of $561 million, a PE ratio of -9.51 and a beta of -0.09. The business has a 50-day moving average price of $10.00 and a two-hundred day moving average price of $9.50.

Theravance Biopharma (NASDAQ:TBPHGet Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. The business had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Research analysts anticipate that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Activity

In other news, SVP Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the sale, the senior vice president now directly owns 336,918 shares in the company, valued at $3,706,098. The trade was a 6.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in shares of Theravance Biopharma by 3.8% during the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company’s stock valued at $556,000 after buying an additional 2,293 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Theravance Biopharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company’s stock valued at $8,121,000 after purchasing an additional 4,823 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Theravance Biopharma by 16.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company’s stock valued at $610,000 after purchasing an additional 9,315 shares during the period. ProShare Advisors LLC bought a new position in shares of Theravance Biopharma in the fourth quarter valued at approximately $119,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Theravance Biopharma by 27.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company’s stock valued at $1,412,000 after purchasing an additional 32,534 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

(Get Free Report)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Further Reading

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.